George Magrath - 17 May 2024 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Chief Executive Officer
Signature: /s/ Amy Rabourn, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 17 May 2024
Net transactions value: +$8,772
Form type: 4
Filing time: 21 May 2024, 16:18:02 UTC
Previous filing: 20 Mar 2024
Next filing: 05 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Purchase	$8,772	+5,000	+1.2%	$1.75	430,000	17 May 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.73 to $1.78, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.73 to $1.78, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.